Daniel Pollyea, MD
Hematology & Oncology · Aurora, CONPI 1801915822
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $222,773 of the $273,767 with a category attached, or 81.4%. 28 manufacturers reported payments, led by AbbVie at 35.2% of the total. Reporting peaked in 2019 at $69,254 and has fallen 55.1% since, to $31,118 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $1185.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$96K
- Daiichi Sankyo Inc.$30K
- Bristol Myers Squibb$30K
- Novartis$24K
- E.r. Squibb & Sons, L.L.C.$18K
- Servier Pharmaceuticals LLC$16K
- plus $61K from 22 others
Across 545 payments — averaging $16,788 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$6.7M
- Bristol Myers Squibb$482K
- Amgen$443K
- Karyopharm Therapeutics Inc.$400K
- Teva Pharmaceuticals USA, Inc.$329K
- Genentech, Inc.$278K
- plus $534K from 14 others
What the payments were for
- Consulting fees$222,77381%
- Speaking & faculty fees$21,3508%
- Travel & lodging$25,2449%
- Food & beverage$4,4012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $96,369 |
| Daiichi Sankyo Inc. | 5 | $29,712 |
| Bristol Myers Squibb | 16 | $29,538 |
| Novartis | 11 | $23,557 |
| E.r. Squibb & Sons, L.L.C. | 6 | $17,680 |
| Servier Pharmaceuticals LLC | 17 | $15,518 |
| Gilead | 8 | $8,366 |
| Taiho Oncology, Inc. | 9 | $6,564 |
| Astellas Pharma US Inc | 5 | $5,280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $4,620 |
| Jazz Pharmaceuticals Inc. | 2 | $4,500 |
| Genentech USA, Inc. | 7 | $4,399 |
| Geron Corporation | 6 | $4,224 |
| Syndax Pharmaceuticals, Inc. | 5 | $3,777 |
| Sanofi US Services Inc. | 1 | $2,909 |
| Janssen Research & Development, LLC | 1 | $2,860 |
| Astellas Pharma Global Development | 1 | $2,652 |
| Agios Pharmaceuticals, Inc. | 1 | $2,175 |
| Pfizer | 1 | $1,875 |
| Rigel Pharmaceuticals, Inc. | 3 | $1,820 |
| Amgen | 4 | $1,668 |
| Genentech, Inc. | 1 | $1,650 |
| Genmab U.S., Inc. | 1 | $785 |
| AstraZeneca | 6 | $586 |
| F. Hoffmann-la Roche AG | 2 | $393 |
| Karyopharm Therapeutics Inc. | 2 | $214 |
| Servier Affaires Medicales | 1 | $50 |
| Janssen Global Services, LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$273,767 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 27 | $791,684 |
| VenclextaVenetoclax | 42 | $617,964 |
| TasignaNilotinib Hcl | 40 | $487,498 |
| InqoviDecitabine/Cedazuridine | 20 | $159,989 |
| SprycelDasatinib | 28 | $126,412 |
| ImbruvicaIbrutinib | 12 | $70,245 |
| Imatinib Mesylate | 21 | $30,851 |
| Granisetron Hcl | 14 | $2,755 |
| Acyclovir | 49 | $881 |
| Fluconazole | 16 | $798 |
| Levofloxacin | 17 | $329 |
| Celecoxib | 11 | $199 |
| Ondansetron Hcl | 22 | $189 |
| Prochlorperazine Maleate | 14 | $132 |
| Potassium Chloride | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Servier Pharmaceuticals LLCTibsovo | $15,518 | $791,68427 claims |
| AbbVieVenclexta | $96,369 | $617,96442 claims |
| NovartisTasigna | $23,557 | $487,49840 claims |
| Taiho Oncology, Inc.Inqovi | $6,564 | $159,98920 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $17,680 | $126,41228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Douglas ReznickAurora$294K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
- Breelyn WilkyAurora$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.